

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1681)

CHANGES IN COMPOSITION OF THE BOARD AND A BOARD COMMITTEE

RESIGNATION OF AN EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (“**Director(s)**”) of Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. AN Yubao (“**Mr. An**”) has resigned from the position of the chairman of the Board, an executive Director and a member of the nomination committee of the Company (the “**Nomination Committee**”) with effect from 9 July 2021, in order to devote more time to his family.

Mr. An has confirmed that he has no claim whatsoever against the Company for fees, compensation for loss of office, remuneration, severance payments, pension, expenses or otherwise and has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) or the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to express its appreciation for the valuable contributions made by Mr. An towards the Company during his tenure of office.

APPOINTMENT OF THE CHAIRMAN OF THE BOARD AND A MEMBER OF THE NOMINATION COMMITTEE

The Board resolved to appoint Mr. AN Meng, an executive Director, as the chairman of the Board and a member of the Nomination Committee in replacement of Mr. An with effect from 9 July 2021.

APPOINTMENT OF A NON-EXECUTIVE DIRECTOR

The Board resolved to appoint Ms. ZHANG Lihua (“**Ms. Zhang**”) as a non-executive Director with effect from 9 July 2021.

Ms. Zhang, aged 44, obtained a doctoral degree of medicine from Southern Medical University in June 2013. Ms. Zhang is currently serving as a deputy chief physician at the affiliated hospital of Southern Medical University. She is also a committee member of the Specialized Committee on Basic Theory of Chinese Association of Integrative Medicine* (中國中西醫結合學會基礎理論專業委員會), an expert member of the Gynecology Quality Control Centre of Traditional Chinese Medicine in Guangdong Province* (廣東省中醫婦科質量控制中心), a director of Guangdong Province Population Culture Promotion Association* (廣東省人口文化促進會) and an executive director of its Entrepreneur Health Culture Professional Committee* (企業家健康文化專業委員會), and an evaluation expert for the High-level Talents in Guangdong Province. Ms. Zhang has been awarded a second prize for the 2019 Guangdong Scientific and Technological Advancement Award* (廣東省科技進步獎二等獎), a second prize for the Excellent Textbook (Higher Education) in China by Ministry of Education* (教育部全國優秀教材(高等教育類)二等獎) and a second prize of Science and Technology Award by Chinese Association of Integrative Medicine* (中國中西醫結合學會科學技術獎二等獎). In 2019, Ms. Zhang was selected as Guangdong Province Outstanding Young Medical Talent* (廣東省傑出青年醫學人才).

Ms. Zhang is the wife of Mr. AN Meng, an executive Director (Mr. AN Meng is the son of Mr. An, a controlling shareholder of the Company). Save as disclosed, Ms. Zhang does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company.

Ms. Zhang has entered into a service agreement with the Company to act as a non-executive director for a term of three years commencing from 9 July 2021 which may be terminated by either party giving not less than three months’ prior notice in writing and is subject to termination provisions contained therein and retirement and re-election in accordance with the articles of association of the Company, the Rules Governing the Listing of Securities on the Stock Exchange and any other applicable laws from time to time. Pursuant to the articles of association of the Company, Ms. Zhang shall hold office only until the next following annual general meeting of the Company after her appointment and may offer herself for re-election at such meeting. According to the service agreement, Ms. Zhang does not receive any director’s remuneration for serving as a non-executive Director, but shall be subject to review by resolution of the Board or Shareholders’ resolution at the general meeting of the Company from time to time.

Save as disclosed in this announcement, Ms. Zhang (i) did not hold any other positions in the Company or its subsidiaries as at the date of this announcement; (ii) did not hold any other directorships in listed public companies in the three years prior to the date of this announcement and (iii) does not hold any other major appointment and professional qualification.

As at the date of this announcement, Ms. Zhang is deemed to be interested in the 211,855,000 ordinary shares of the Company (“**Shares**”) in which her spouse, Mr. AN Meng, is interested, representing approximately 25.76% of the issued share capital of the Company as at the date of this announcement in aggregate. Among the 211,855,000 Shares in which Mr. AN Meng is interested, 14,531,000 Shares are held by Mr. AN Meng as beneficial owner and 197,324,000 Shares are held by Central Success Developments Limited. The entire issued share capital of Central Success Developments Limited is owned by Aali Resources Limited which is held in the name of BOS Trustee Limited as a trustee of a discretionary trust of which Mr. An is the founder and Mr. AN Meng is one of the beneficiaries. Save as disclosed above, Ms. Zhang does not have any interest in the Shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in this announcement, there is no other information that needs to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules and there is no other matter relating to Ms. Zhang’s appointment that needs to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to welcome Ms. Zhang for joining the Board.

By order of the Board
Consun Pharmaceutical Group Limited
AN Meng
Chairman

Hong Kong, 9 July 2021

As at the date of this announcement, the Board comprises Mr. AN Meng, Ms. LI Qian, Professor ZHU Quan and Mr. XU Hanxing as executive Directors; Ms. ZHANG Lihua as non-executive Director; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHEN Yujun as independent non-executive Directors.

* *for identification only*